A 43-year-old woman with severe pancytopenia and a splenic hematoma.

Autor: Planken, E., Ottolander, G., Kluin, P., Bieger, R., Planken, E V, den Ottolander, G J, Kluin, P M

Publikováno v: Annals of Hematology; 1994, Vol. 69 Issue 5, p265-270, 6p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Neoplastic Cell Activation And Proliferative Response To CD40-Ligand Characterize Recurrent....

Autor: Aizman, Irina, Many, Amira, Rosenthal, Esther, Schiby, Ginette, Goldberg, Iris, Barak, Vivian, Ramot, Bracha, Kaufmann, Yael

Publikováno v: Leukemia & Lymphoma. Feb2000, Vol. 36 Issue 5/6, p613. 11p. 1 Chart, 4 Graphs.

CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation.

Autor: Elmetwali T; Institute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK. elmetwaa@liverpool.ac.uk., Salman A; Institute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.; National Research Centre, 12662, Dokki, Giza, Egypt., Wei W; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.; Department of Biosciences, Durham University, Durham, DH1 3LE, UK., Hussain SA; Sheffield Academic Unit of Oncology Department of Oncology and Metabolism Medical School, University of Sheffield, Sheffield, S10 2 RX, UK., Young LS; Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK., Palmer DH; Institute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 2nd Floor Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.; Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY, UK.

Publikováno v: Scientific reports [Sci Rep] 2020 Jan 15; Vol. 10 (1), pp. 342. Date of Electronic Publication: 2020 Jan 15.

Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program

Autor: Jules L.L.M. Coenen, Evert-Jan F. M. de Kruijf, Peter A. W. te Boekhorst, Joost T. M. de Wolf, Gerjo A. Velders, Fenna H. Heyning, Alex L. Imholz, Gert J. Ossenkoppele, Canan Alhan, M. C. Kappers-Klunne, Christine M. Segeren, Jan Koedam, Wies L. Vasmel, Ankie M. T. Van der Velden, Gerda Veth, Gerwin Huls, Arjan A. van de Loosdrecht, Imane Abouyahya, Theresia M. Westers, Erwin V. Planken, H.R. Koene, Petra Muus

Publikováno v: Leukemia & Lymphoma, 54, 4, pp. 874-7
Abouyahya, I, Alhan, C, Westers, T M, te Boekhorst, P A, Kappers-Klunne, MC, Coenen, J L, Heyning, F H, Huls, G A, de Wolf, JT, Imholz, A L, Koene, H R, Veth, G, de Kruijf, E J F M, Muus, P, Planken, E V, Segeren, C M, Vasmel, W L, van der Velden, A M, Velders, G A, Koedam, J, Ossenkoppele, G J & van de Loosdrecht, A A 2013, ' Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program ', Leukemia and Lymphoma, vol. 54, no. 4, pp. 874-877 . https://doi.org/10.3109/10428194.2012.728702
Leukemia and Lymphoma, 54(4), 874-877. Informa Healthcare
Leukemia & Lymphoma, 54, 874-7
Leukemia and Lymphoma, 54(4), 874-877. TAYLOR & FRANCIS LTD
Leukemia & Lymphoma, 54(4), 874-877

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematopoietic stem cell disorders characterized by dysplasia resulting in cytopenia in one or more cell lineages. The World Health ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23ed24a02b861b0d8dad261ce450f08
https://pubmed.ncbi.nlm.nih.gov/22971215